Buchumschlag

TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells

Imiquimod and resiquimod represent Toll-like receptor (TLR) 7 and 8 agonists, which emerged as attractive candidates for tumor therapy. To elucidate immune cells, which mainly contribute to TLR7/8-mediated antitumoral activity, we investigated the impact of imiquimod and resiquimod on native human 6...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Jähnisch, Hanka (VerfasserIn) , Wehner, Rebekka (VerfasserIn) , Tunger, Antje (VerfasserIn) , Kunze, Anja (VerfasserIn) , Oehrl, Stephanie (VerfasserIn) , Schäkel, Knut (VerfasserIn) , Rohayem, Jacques (VerfasserIn) , Bornhäuser, Martin (VerfasserIn) , Tonn, Torsten (VerfasserIn) , Bachmann, Michael (VerfasserIn) , Schmitz, Marc (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 9 February 2013
In: Cancer letters
Year: 2013, Jahrgang: 335, Heft: 1, Pages: 119-127
ISSN:1872-7980
DOI:10.1016/j.canlet.2013.02.003
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.canlet.2013.02.003
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0304383513001146
Volltext
Verfasserangaben:Hanka Jähnisch, Rebekka Wehner, Antje Tunger, Anja Kunze, Stephanie Oehrl, Knut Schäkel, Jacques Rohayem, Martin Bornhäuser, Torsten Tonn, Michael Bachmann, Marc Schmitz
Beschreibung
Zusammenfassung:Imiquimod and resiquimod represent Toll-like receptor (TLR) 7 and 8 agonists, which emerged as attractive candidates for tumor therapy. To elucidate immune cells, which mainly contribute to TLR7/8-mediated antitumoral activity, we investigated the impact of imiquimod and resiquimod on native human 6-sulfo LacNAc (slan) dendritic cells (DCs). We found that both TLR7/8 agonists significantly improve the release of various proinflammatory cytokines by slanDCs and promote their tumor-directed cytotoxic activity. Furthermore, resiquimod efficiently augmented the ability of slanDCs to stimulate T cells and natural killer cells. These results indicate that imiquimod and resiquimod trigger various immunostimulatory properties of slanDCs, which may contribute to their antitumor effects.
Beschreibung:Gesehen am 24.03.2021
Beschreibung:Online Resource
ISSN:1872-7980
DOI:10.1016/j.canlet.2013.02.003

Ähnliche Einträge